Oragenics signs LOI to license CardioDialysis from Sigyn Therapeutics for TBI

ORAGENICS INC

LOI grants Oragenics exclusive license for CardioDialysis blood purification tech in TBI and chronic neurodegenerative diseases.
Consideration: 3,250,000 shares of preferred stock convertible 1:1 to common, plus 3% royalty for 6 years post-FDA clearance.
Target closing within 90 days; Sigyn exclusivity during that period; subject to due diligence, board approvals, and NYSE American rules.
Oragenics also advancing ONP-002 (Phase IIa intranasal neurosteroid); combined approach targets TBI inflammation on both sides of BBB.
No FDA-approved pharmacological treatment for concussion/mTBI; 69 million brain injuries occur annually worldwide.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.